Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03973775 · ClinicalTrials.gov registry record · Phase 3
A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies
A Phase 3 study of Scabies, sponsored by Saptalis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 126
- Enrollment target
- 5
- Study locations
NCT03973775 is a Phase 3 study of Scabies that has completed, run by Saptalis Pharmaceuticals. The registered enrollment target is 126 participants. The trial reports 5 study locations across 3 states.
The verdict
NCT03973775, a Phase 3 study of Scabies, has completed, sponsored by Saptalis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 126 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase III study was conducted to establish the clinical bioequivalence of Permethrin Cream 5% and Elimite™ in the treatment of scabies following a single application.
Conditions Studied
Interventions
- DRUG Permethrin Cream 5%
Study Locations (5)
California
- Universal Biopharma Research Institute Inc. - Dinuba
- Long Beach Clinical Trials Services, Inc. - Long Beach
- Havana Research Institute - Pasadena
Florida
- SouthCoast Research Center, Inc (Clinical Site & Drug Shipment Facility) - Miami
Texas
- West Houston Clinical Research Service - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2018-04-10 |
| Est. Completion | 2018-12-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03973775
The ClinicalTrials.gov registry entry for NCT03973775 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saptalis Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Scabies appearing as the primary indexed condition, and to 1 intervention - of which Permethrin Cream 5% is the first listed.
NCT03973775 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT03973775 about?
NCT03973775 is a clinical study titled "A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies". This phase III study was conducted to establish the clinical bioequivalence of Permethrin Cream 5% and Elimite™ in the treatment of scabies following a single application.
What is the current status of trial NCT03973775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 126 participants. The study started on 2018-04-10. Estimated completion is 2018-12-06.
What conditions does trial NCT03973775 study?
This clinical trial studies the following conditions: Scabies.
What interventions are being tested in trial NCT03973775?
The interventions under investigation include: Permethrin Cream 5% (DRUG).
Who is sponsoring clinical trial NCT03973775?
This trial is sponsored by Saptalis Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03973775 being conducted?
This trial has 5 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scabies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.